Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Exelixis: NCCN Change Supports Broader Use Of Cabometyx In Kidney Cancer

Sep 08 2018

• By Emily Hayes

Helping Hand_169455167_1200.jpg — Updated practice guidelines give cabozantinib a boost in kidney cancer.

Related Content

First In 10 Years, But Lenvima's First-Line Liver Label Could Be Challenged Soon

Aug 17 2018

Exelixis' CELESTIAL Liver Trial Succeeds, But Can Cabozantinib Compete?

Jan 23 2018

Exelixis' Strong Cabometyx Start Signals Changing Of Guard In Kidney Cancer Market

Aug 05 2016

Exelixis Eyes Liver Cancer OK To Help Drive Cabometyx Sales

Mar 16 2018

Bristol Touts Opdivo's Stability – And Diversity – In Strong Q2

Jul 27 2018

Related Companies

Exelixis, Inc.

Bristol Myers Squibb Company

Pfizer Inc.

Bayer AG

Amgen, Inc.

Merck & Co., Inc.

Eisai Co., Ltd.

Additional Topics

Reimbursement Commercial Research & Development Sales & Earnings Cancer BioPharmaceutical

More from Drug Pricing

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window